Comparing Piperacillin Tazobactam and Meropenem for Bloodstream Infections Caused by Cephalosporin-Resistant Enterobacteriaceae A Phase 4 Randomized Trial to Test Treatment Effectiveness

What this Trial Is About

Researchers are evaluating the best treatment for bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae bacteria, specifically looking at whether piperacillin-tazobactam is as effective as meropenem. The study focuses on adults with blood infections due to E. coli or Klebsiella species that are resistant to certain antibiotics but susceptible to both study drugs. The trial aims to determine if piperacillin-tazobactam is not worse than meropenem in treating these infections. Participants are randomly assigned to receive either piperacillintazobactam at a dose of 4.5 grams four times a day or meropenem at 1 gram three times a day. Both treatments are given to treat the bloodstream infection during the study. The trial includes patients with both community and hospital-acquired infections and excludes those with certain severe conditions or prior infections not fully treated. During the study, participants are monitored for outcomes such as death within 30 days and treatment failure within 7 days after starting treatment. Additional assessments include mortality at 14 and 90 days, microbiological outcomes, infection relapses, hospital readmissions, antibiotic use, resistance development, and adverse events. The study collects detailed data over 90 days to evaluate the safety and impact of these antibiotic treatments.

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)